| INO Snapshot | |
|---|---|
| Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA drugs to treat and protect people from diseases associated with the human papillomavirus (HPV), cancer, and infectious diseases. | |
| VALUATION DATA | |
| Market Capitalization | $238,378,000 | Price to Sales | 3.00 |
| Earnings per Share | $-6.0900 |
| PE Ratio | None |
| PRICE DATA | |
| Most Recent Close | $9.6800 |
| 52 Week High | $309.82 |
| 52 Week Low | $2.197 |
| 50-Day Moving Average | $171.5 |
| 200-Day Moving Average | $-1.094 |
| All data are from Alpha Vantage as of today. For more infomation on INO see Stock Dividend, Valuation, Price and Financial Data for Investors | |
Custom Search